GSK4418959

Phase 2Small molecule

GSK

GSK4418959 is one of 37 small molecule programs targeting Effectiveness. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EffectivenessActive, not recruiting

EffectivenessPhase 2

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Effectiveness

#DrugCompanyPhaseTrials

Kesimpta

Novartis

Phase 3

2 2

Mounjaro

Eli Lilly

Phase 3

1 3

Actos

Takeda

Phase 3

1 4

Elucirem

GGuerbet

Phase 3

1 5

Nicotine Free Cigarettes

Pfizer

Phase 3

3 6

Lidocain

Bayer

Phase 3

1 7

Botulinum Toxin a

GSK

Phase 3

1 8

Pneumococcal Conjugate Vaccine

Novartis

Phase 3

1 9

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 10

DTG/3TC

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness1 trial

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1/2·NCT06710847·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GSK4418959. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK4418959 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK4418959. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GSK4418959

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News